Lets begin with simple things first
So Basic EPS = (Net Income - Preferred Dividend )/Total Shares Outstanding
Now as Preferred shares are cumulative then , even if
dividends are not declared they will be deducted into the
calculations .
So, Preferred Dividends = 6% of 1,162,500 = $69750
EPS = (1,520,000-69750)/ 990,000
EPS = 1.4648 = $1.46 rounded off
Now lets move to Diluted EPS
Diluted EPS is calculated to get knowledge about the change in EPS when all the dilutive securites are converted into stocks such as preferred shares , bonds and options , how will EPS change
Now 9% convertible Bonds are dilutive , so interest(after tax)
deducted from net income will be added back to it
So interest income will be 9% of $5,090,000=$458,100
But tax had to be deducted @20 % so interest would be $458,100*(1-0.20) = $458,100*0.8 = $366480
Now as each $1000 is equal to 50 common shares and we total have bonds worth $5,090,000 , so we get around
= 5090,000*50 / 1000 = 254,500 shares
Now check if its dilutive or anti dilutive = 366480 / 254500 =1.44 , its less than 1.46 , this means its dilutive security and would be added in our calculations .
Now talk about other dilutive security i.e options
(So we consider options as exercised while calculating
dilutive EPS even when they are not exercised., we use a treasury
method to calculate the increase in shares.
Now hypothetically assume we have options to purchase 190,000
shares @16 each so that would be = $3,040,000
Now as shares price is around $20 we use our $3,040,000 to get shares @20 each that would be around 152,000 shares
we had to get 190,000 shares , we had 152,000 shares , so in total increase in shares is 190,000-152,000 = 38000 shares)
Now we could do this shortcut way , (market price- option price) / market price * no. of options = 20-16/20 *190,000 = 38000
Now Diluted EPS = (Net income - preferred dividends + Net interest income) / (Average common shares+ Converted bonds+ converted shares )
Diluted EPS = (1,520,000- 69750 + 366480) / (990,000 + 254500 + 38000) =1816730/ 1282500 = 1.416 =1.42 rounded off
16.2 #3 PLEASE SHOW ALL WORK Amy Dyken, controller at Swifty Pharmaceutical Industries, a public company,...
Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% $1,020,000 9% convertible bonds payable 5,020,000 11% bonds payable 6,120,000 Total long-term debt $12,160,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Wildhorse Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Wildhorse’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Wildhorse Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 9% convertible bonds payable 4,970,000 10% bonds payable 5,980,000 Total long-term debt $11,970,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Bridgeport Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Bridgeport’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Bridgeport Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $990,000 9% convertible bonds payable 5,040,000 10% bonds payable 6,080,000 Total long-term debt $12,110,000 Shareholders’ equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Sunland Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sunland's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sunland Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% 9% convertible bonds payable 10% bonds payable Total long-term debt $990,000 5,040,000 6,080,000 $12,110,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Amy Dyken, controller at Blossom Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Blossom’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Blossom Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Waterway Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Waterway’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Waterway Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,020,000 8% convertible bonds payable 5,080,000 10% bonds payable 6,110,000 Total long-term debt $12,210,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken, controller at Sandhill Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sandhill’s financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Sandhill Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 10% $1,010,000 9% convertible bonds payable 5,030,000 10% bonds payable 5,990,000 Total long-term debt $12,030,000 Shareholders’ equity Preferred stock, 6% cumulative, $50 par...
Amy Dyken controller at Sheridan Pharmaceutical Industries, a public company is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Sheridan financial statements Below is selected financial information for the fiscal year ended June 30, 2020. Sheridan Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term diebt Notes payable, 10% 9X convertible bonds payable 10% bonds payable Total long-term debt $1.000.000 5,050,000 5.920,000 $11.970,000 Shareholders' equity Preferred stock, 5% cumulative, $50 par...
Problem 16-05 Amy Dyken, controller at Monty Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Monty's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Monty Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 Long-term debt Notes payable, 11% 8% convertible bonds payable 11% bonds payable Total long-term debt $980,000 5,030,000 6,100,000 $12,110,000 Shareholders' equity Preferred stock, 6% cumulative,...